These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35147819)

  • 1. Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.
    Czaja AJ
    Dig Dis Sci; 2022 Nov; 67(11):4979-5005. PubMed ID: 35147819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: targeting the B cell activation system in autoimmune hepatitis.
    Czaja AJ
    Aliment Pharmacol Ther; 2021 Oct; 54(7):902-922. PubMed ID: 34506662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.
    Czaja AJ
    Dig Dis Sci; 2021 Aug; 66(8):2493-2512. PubMed ID: 32833154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.
    Czaja AJ
    Dig Dis Sci; 2022 Apr; 67(4):1163-1186. PubMed ID: 33835375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.
    Ly S; Nedosekin D; Wong HK
    Am J Clin Dermatol; 2023 Mar; 24(2):247-273. PubMed ID: 36630066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
    Bellinvia S; Ashraf M; Polosa R; Edwards C
    Immunotherapy; 2017 Nov; 9(14):1133-1142. PubMed ID: 29067885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
    Terrier B; Mouthon L
    Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis.
    Czaja AJ
    Autoimmunity; 2019 Jun; 52(4):144-160. PubMed ID: 31298041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part II.
    Czaja AJ
    Inflamm Allergy Drug Targets; 2012 Oct; 11(5):351-63. PubMed ID: 22563780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
    Czaja AJ
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1286-1304. PubMed ID: 32363674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update.
    Prieto-Peña D; Dasgupta B
    Pol Arch Intern Med; 2021 Feb; 131(2):171-181. PubMed ID: 32550671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapy for refractory scleritis: a new treatment perspective.
    de Fidelix TS; Vieira LA; de Freitas D; Trevisani VF
    Int Ophthalmol; 2015 Dec; 35(6):903-12. PubMed ID: 26319144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of infliximab biosimilar Inflectra
    Schimmelpennink MC; Vorselaars ADM; van Beek FT; Crommelin HA; Deneer VHM; Keijsers RGM; Veltkamp M
    Respir Med; 2018 May; 138S():S7-S13. PubMed ID: 29496351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases.
    Mostkowska A; Rousseau G; Raynal NJ
    FASEB J; 2024 Mar; 38(5):e23536. PubMed ID: 38470360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT-P10 (Truxima™): A Rituximab Biosimilar.
    Deeks ED
    BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.